Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916187 | 1.00 | GPR119 (0.57) | GPR119TBK1IKBKEJAK2JAK1 | |
| SCHEMBL917510 | 0.85 | GPR119 (0.41) | GPR119TACR3USP30ACKR3 | |
| SCHEMBL967405 | 0.84 | GPR119 (0.58) | GPR119JAK2JAK1TACR3HDAC4 | |
| SCHEMBL1993504 | 0.81 | RORC (0.49) | USP30 | |
| SCHEMBL503532 | 0.81 | RORC (0.49) | USP30 | |
| SCHEMBL8062043 | 0.81 | USP2 (0.44) | GPR119USP30 | |
| SCHEMBL503531 | 0.81 | RORC (0.49) | USP30 | |
| SCHEMBL323889 | 0.79 | USP2 (0.46) | GPR119USP30 | |
| SCHEMBL497161 | 0.79 | USP2 (0.46) | GPR119USP30 | |
| SCHEMBL503547 | 0.78 | NR1H2 (0.45) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197877-B1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-1, 2, 4-OXADIAZOL-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI SA (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-8288383-B2 | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20110003988-A1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIM-IDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003988-A1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIM-IDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | MAPT, PSEN2, PSEN1 | GPR119 2425/4885TBK1 153/4885IKBKE 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.